Figure 5.

Treatment with rosiglitazone sensitizes to the metabolic effects of FGF21. To assess the potential for interaction between FGF21 and rosiglitazone we compared treatment with either agent alone versus a combination of the two. Following treatment we examine body mass change (A), plasma glucose (B), insulin (C), Cholesterol (D) and free fatty acids (E) in addition to change in total water (F) and fat mass gain/loss (G). Statistical significance from vehicle was denoted by * while differences from rosiglitazone alone are indicated with †. Differences were considered significant when P≤0.05.